China Accepts Boan Biotechnology's Biologics License Application for Type 2 Diabetes Drug

China's medical products administrator accepted Shandong Boan Biotechnology's (HKG:6955) biologics license application for its BA5101 dulaglutide injection for type 2 diabetes patients in China, accor

MT Newswires00:07 ET

The marketing application for Dulacopeptide injection independently developed by Boan Biotech has been accepted

Boan Biotech (06955) announced that the marketing application for the company's self-developed duracopeptide injection (BA5101) has been accepted by the Drug Evaluation Center of the China National Drug Administration. According to reports, BA5101 is a biosimilar of Trulicity (Trulicity) for blood sugar control in adult type 2 diabetics. As far as the company knows, BA5101 is currently the first Trulicity (Trulicity) biosimilar to be submitted for marketing in China. It is also the first Trulicity (Trulicity) biosimilar in the world to complete phase III clinical trials. The development progress is leading

新浪港股19:29 ET

Boan Biotech (06955.HK): Dulacopeptide Injection (BA5101) application accepted for listing in China

Gelonghui, May 27丨Boan Biotech (06955.HK) announced that the marketing application for the company's self-developed duracopeptide injection (BA5101) has been accepted by the Drug Evaluation Center of the China National Drug Administration. BA5101 is a biosimilar to Trulicity for blood sugar control in adults with type 2 diabetes. As far as the company knows, BA5101 is currently the first Trulicity (Trulicity) biosimilar to be submitted for marketing in China, and the first Trulicity (Trulicity) biosimilar in the world to complete phase III clinical trials

Gelonghui FinanceMay 27 08:59 ET

Shandong Boan Biotechnology GCTB Drug NMPA's Marketing Approval

Shandong Boan Biotechnology (HKG:6955) said China's National Medical Products Administration (NMPA) approved its denosumab injection (120mg) for marketing, according to a Monday filing on the Hong Ko

MT NewswiresMay 27 03:46 ET

Boan Biotech's Boluojia Wins NMPA Approval

TipRanksMay 27 00:38 ET

Boan Biotech (06955.HK) in the field of oncology has been approved and marketed for the treatment of bone giant cell tumors that cannot be surgically resected or where surgical resection may cause serious dysfunction

On May 27, Ge Longhui | Boan Biotech (06955.HK) announced that the company's self-developed dysulumab injection (120mg) - Boroga has been approved by the China National Drug Administration for the treatment of bone giant cell tumors that cannot be surgically removed or may cause serious functional impairment, including adults and young patients with mature bone development (defined as at least 1 mature bone and body weight greater than 45 kg). Boroga is a biosimilar of Agave (English product name: XGEVA). Its development process strictly follows biosimilar relationships in China, the United States, the European Union, and Japan

Gelonghui FinanceMay 27 00:22 ET